Pharmacodynamic Drug–Drug Interactions
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pharmacodynamic drug–drug interactions (DDI s) occur when the pharmacological effect of one drug is altered by that of another drug in a combination regimen. DDI s often are classified as synergistic, additive, or antagonistic in nature, albeit these terms are frequently misused. Within a complex pathophysiological system, the mechanism of interaction may occur at the same target or through alternate pathways. Quantitative evaluation of pharmacodynamic DDI s by employing modeling and simulation approaches is needed to identify and optimize safe and effective combination therapy regimens. This review investigates the opportunities and challenges in pharmacodynamic DDI studies and highlights examples of quantitative methods for evaluating pharmacodynamic DDI s, with a particular emphasis on the use of mechanism‐based modeling and simulation in DDI studies. Advancements in both experimental and computational techniques will enable the application of better, model‐informed assessments of pharmacodynamic DDI s in drug discovery, development, and therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“All of these components interact with each other; the tumor- associated cellular components engage in autocrine and paracrine signaling networks, and interact with the extracellular matrix exerting its effects on tumor and stromal cell behavior.(17,18) In one example, a sequential regimen consisting of sustained epide…”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 2×
“All of these components interact with each other; the tumor- associated cellular components engage in autocrine and paracrine signaling networks, and interact with the extracellular matrix exerting its effects on tumor and stromal cell behavior.(17,18) In one example, a sequential regimen consisting of sustained epide…”
BackgroundDrug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 2×
“In smaller- scale studies, such as is common in animalbased research or clinical research, the terms “additive” and “synergistic” are often misused.(23) Frequently they are used to describe an “enhancement” of effect suggested by a statistically greater response to a drug combination as compared with monotherapy.”
BackgroundTHE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394 · cited 1×
“For example, when ibuprofen was administered daily with aspirin, the aspirinmediated inhibition of platelet aggregation was reported to be blocked.(44) The mechanism of this antagonistic interaction was characterized quantitatively using a nonlinear mixed effect (population) model that included the turnover of the dru…”
MethodEnvironment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · cited 1×
“Tumor- microenvironment crosstalk also plays a role in drug resistance.(63) Picco and colleagues investigated intrinsic and environmentmediated drug resistance (EMDR) in B-Raf proto-oncogene, serine/ threonine kinase (BRAF)–mutated melanoma xenografts and proposed a mathematical model that characterized the DDI betwee…”
BackgroundPalmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Friedrich, C. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12056 · Cited by 87
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Xiong, G., Yang, Z., Yi, J., Wang, N., Wang, L., Zhu, H., Wu, C., Lu, A., Chen, X., Liu, S., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab880 · Cited by 133
Spanakis, M., Alon-Ellenbogen, D., Ioannou, P., & Spernovasilis, N. (2023) · Pharmacy · doi:10.3390/pharmacy11040130 · Cited by 3
Metadata
- Authors
- Niu, J., Straubinger, R. M., & Mager, D. E.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2019-04-26
- Volume
- 105
- Issue
- 6
- Pages
- 1395-1406
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2923257762
- Cited by
- 250
- References
- 11
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.